Ribeiro, Gabriela
Maia, Ana
Cotovio, Gonçalo
Oliveira, Francisco P. M.
Costa, Durval C.
Oliveira-Maia, Albino J.
Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (PTDC/MED-NEU/31331/2017, SFRH/BD/128783/2017, SFRH/BD/144508/2019, SFRH/BD/130210/2017)
European Research Council (Grant agreement No. 950357)
Article History
Received: 27 July 2022
Accepted: 8 March 2023
First Online: 27 March 2023
Competing interests
: GR, AM, GC, FPMO, DCC did not report conflicts of interest. AJO-M was the national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019–2020), of a trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd (EudraCT No. 2017-003288-36), and of a trial of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT No.: 2019-002992-33), and is a recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests.